Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fludarabine-based reduced-intensity conditioning for allogeneic stem cell transplantation in myelofibrosis
2007-001413-42Phase 2Active
- Sponsor
- Papa Giovanni XXIII Hospital
- Start
- Jul 2007
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of fludarabine in myelofibrosis (MF) and post-polycythemia vera myelofibrosis (PPV-MF), sponsored by Papa Giovanni XXIII Hospital. Primary endpoints: Progression-free survival and Overall survival. Started Jul 2007; status: active.
02
Drugs
fludarabine
03
Conditions
myelofibrosis (MF)post-polycythemia vera myelofibrosis (PPV-MF)
Beyond the preview
Go deeper on 2007-001413-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-001413-42.